Comment from Knoa Pharma LLC

Summary: Knoa Pharma LLC supports the FDA's drug repurposing initiative, specifically advocating for the inclusion of substance use disorders (SUDs) as a priority disease area. They propose three specific candidates for repurposing: varenicline for nicotine dependence, prescription stimulants for stimulant use disorders, and nalmefene for alcohol use disorder.